MyoRenew Advance
Also known as: MyoRenew Advance (branded product name), Iltamiocel, Muscle-derived cell technology, Autologous Muscle-Derived Cells (AMDC)
Overview
Autologous Muscle-Derived Cells (AMDC), specifically iltamiocel, represent a form of regenerative cell therapy that utilizes a patient's own muscle cells to restore muscle function. While 'MyoRenew Advance' appears to be a branded product name, the underlying technology involves the use of these personalized cells, primarily developed by Cook MyoSite. This therapy is not a traditional oral supplement but rather a sophisticated cell-based treatment. It is currently under clinical investigation for its potential to treat muscle dysfunction in conditions such as female stress urinary incontinence, fecal incontinence, and oropharyngeal dysphagia. The technology has undergone over 20 years of clinical research, with more than 700 participants enrolled in various trials, indicating a mature research pipeline. However, specific independent, peer-reviewed clinical data for 'MyoRenew Advance' itself is not publicly available, as it seems to refer to the application of this cell therapy.
Benefits
The primary benefits of Autologous Muscle-Derived Cell (AMDC) technology, such as iltamiocel, are centered on the potential restoration of muscle function in specific clinical conditions. Clinical trials are investigating its efficacy in treating muscle dysfunction associated with urinary incontinence (both stress and fecal) and oropharyngeal dysphagia (swallowing difficulties). While quantitative effect sizes and detailed efficacy data are not publicly available, the ongoing clinical research with over 700 participants suggests a promising approach for patients suffering from these muscle-related disorders. The therapy is highly targeted, aiming to repair and regenerate damaged muscle tissue, offering a personalized treatment option for these specific populations. No broad secondary benefits or general supplement effects are documented for 'MyoRenew Advance' as it is not a traditional supplement.
How it works
Autologous Muscle-Derived Cells (AMDC) function by utilizing a patient's own muscle cells to regenerate or repair damaged muscle tissue. The mechanism involves harvesting muscle cells from the patient, expanding them in vitro, and then reintroducing them into the affected muscle area. These cells are believed to integrate into the existing muscle tissue, promoting functional recovery by potentially forming new muscle fibers or supporting the repair of existing ones. The therapy primarily interacts with the muscular system, specifically targeting skeletal muscles involved in critical functions like continence and swallowing. The exact molecular targets are not explicitly detailed, but the process is presumed to involve pathways related to muscle cell proliferation, differentiation, and integration.
Side effects
The safety profile of Autologous Muscle-Derived Cell (AMDC) technology, as studied in clinical trials with over 700 participants, is under monitored investigation. However, detailed adverse event data, including common, uncommon, or rare side effects, are not publicly reported in the available literature. As this is a cell therapy rather than an oral supplement, traditional drug interactions are not applicable. Contraindications are also not specified in the provided information. Special population considerations revolve around the specific patient groups targeted in the clinical trials, namely individuals with muscle dysfunctions related to urinary/fecal incontinence and swallowing difficulties. Comprehensive safety data would typically be released upon completion and publication of the clinical trials.
Dosage
Traditional dosage guidelines, as understood for oral supplements, are not applicable to Autologous Muscle-Derived Cell (AMDC) therapy. Dosing in cell therapy involves specific cell counts and precise delivery methods, typically via injection or direct cell delivery into the target muscle tissue, rather than oral ingestion. Minimum effective doses, optimal dosage ranges, and maximum safe doses are not publicly available, as these are determined within the controlled environment of ongoing clinical trials. Timing considerations and form-specific recommendations are also part of the proprietary clinical protocol and are not disclosed. Absorption factors and required cofactors, relevant for oral supplements, are not pertinent to this cell-based therapeutic approach.
FAQs
Is MyoRenew Advance a traditional oral supplement?
No, 'MyoRenew Advance' appears to be a branded name associated with autologous muscle-derived cell therapy, which is a medical procedure involving a patient's own cells, not a conventional oral supplement.
Is there peer-reviewed evidence supporting MyoRenew Advance?
Independent, peer-reviewed randomized controlled trials or meta-analyses specifically on 'MyoRenew Advance' as a supplement were not found. Evidence pertains to the underlying cell therapy technology, which is in clinical trials.
What conditions might it help?
The related autologous muscle-derived cell technology is being investigated for treating muscle dysfunction in conditions such as female stress urinary incontinence, fecal incontinence, and oropharyngeal dysphagia.
Is it commercially available?
The underlying autologous muscle-derived cell technology is still under clinical investigation and is not yet commercially available as a widely accessible treatment or supplement.
Research Sources
- https://www.cookmyosite.com/clinical-trials – This source details Cook MyoSite's ongoing clinical trials for their autologous muscle-derived cell (AMDC) technology, iltamiocel. It highlights the use of a patient's own muscle cells for regenerative purposes, with over 700 participants enrolled across various studies for conditions like urinary and fecal incontinence and dysphagia. The research is in an advanced stage, focusing on the potential to restore muscle function.
- https://www.cookmyosite.com/clinical-research – This page provides an overview of Cook MyoSite's extensive clinical research in autologous muscle-derived cell technology. It emphasizes over 20 years of development and the personalized nature of the regenerative therapy. The summary indicates a robust research pipeline aimed at addressing muscle dysfunction, though specific efficacy and safety data from independent, published trials are not detailed.
